Less than a week after Frequency Therapeutics said it had cut a licensing deal with a big Japanese drug maker, the Woburn biotech announced Tuesday that it has raised $62 million in venture capital from investors enticed by the firm’s efforts to combat hearing loss.

The fundraising round, which is Frequency’s third, means it has collected a total of $147 million from investors. And that’s separate from the $80 million that the four-year-old company will receive up front in the deal it just signed with Tokyo-based Astellas Pharma (ALPMY) to help develop and market Frequency’s experimental drug outside the United States.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy